The early stages of weight loss are associated with a reduction in blood pressure, and the mechanisms mediating this reduction remain unclear. Platelet free calcium levels, [Ca 2+ ]j, have been reported to be elevated in essential hypertension and to decrease with pharmacological treatment of the hypertension. In the current study, 18 obese subjects had measurements of blood pressure, forearm blood flow, forearm vascular resistance, and both basal platelet [Ca 2+ Ji and [Ca 2+ ]j responses to vasopressin during 12 weeks on a very low calorie (3,360 kj, or 800 kcal) diet. Weight reduction was associated with reduction in mean arterial blood pressure at 3-4 weeks. There were associated reductions in forearm vascular resistance and platelet [Ca 
The early stages of weight loss are associated with a reduction in blood pressure, and the mechanisms mediating this reduction remain unclear. Platelet free calcium levels, [Ca 2+ ]j, have been reported to be elevated in essential hypertension and to decrease with pharmacological treatment of the hypertension. In the current study, 18 obese subjects had measurements of blood pressure, forearm blood flow, forearm vascular resistance, and both basal platelet [Ca 2+ Ji and [Ca 2+ ]j responses to vasopressin during 12 weeks on a very low calorie (3,360 kj, or 800 kcal) diet. Weight reduction was associated with reduction in mean arterial blood pressure at 3-4 weeks. There were associated reductions in forearm vascular resistance and platelet [Ca 2+ L as well as increases in forearm blood flow at 3-4 weeks of the diet. Increased forearm blood flow was correlated with weight loss. Vasopressin-induced platelet [Ca 2+ ]i responses increased, which correlated with the reduction in mean arterial pressure at 7-8 weeks of weight loss. Assuming that platelet [Ca 2+ L metabolism reflects vascular smooth muscle cell [Ca 2+ ]| metabolism, the data suggest that blood pressure reduction after weight loss may be related to reduced vascular smooth muscle cell [ with a reduction in blood pressure independent of effects of salt restriction. 1 -11 This reduction in blood pressure in association with caloric restriction is associated with a reduction in plasma renin activity 4 -8 and sympathetic nervous system activity. 5 -8 The renin-angiotensin system and the sympathetic nervous system affect blood pressure by increasing peripheral vascular resistance, 1213 as well as by promoting renal reabsorption of sodium and water and by interfering with the pressure-natriuresis response. 1415 Finally, the enhanced sympathetic nervous system activity seen in obesity 616 may increase blood pressure through trophic effects on blood vessels that render them more responsive to vasoconstrictor stimuli. 17 Results from several studies have suggested that hypertension associated with obesity is characterized by abnormalities in cell cation (e.g., calcium and sodium) metabolism and that weight loss and associated reductions in blood pressure are accompanied by corrections : both share an a 2 -adrenergic receptor-cyclase system 25 and a Ca 2+ -dependent contraction-coupling mechanism. 26 Accordingly, the present study was designed to evaluate the effects of weight loss on blood pressure, peripheral vascular resistance, and platelet [Ca 2+ ]; metabolism in 18 obese subjects.
Methods
Eighteen subjects undergoing a weight-reduction program at Wayne State University were included in this study after we obtained approval from the institutional review committee and informed consent from the subjects, in accordance with our institutional guidelines. Potential subjects (>30% of calculated ideal body weight) were excluded if they had insulin-dependent diabetes mellitus, cardiac disease, or severe hypertension (systolic blood pressure >180 mm Hg, diastolic >114 mm Hg) or were taking either oral hypoglycemic or antihypertensive agents. Clinical characteristics of the study population are given in Table 1 . Hemodynamic and biochemical determinations, as described below, were made before subjects began a very low calorie (3,360 kJ, or 800 kcal) liquid diet (VLCD) (Optifast, Delmar, Minn.) and at 3-4 weeks, 7-8 weeks, and 11-12 weeks after the diet was begun. All subjects were monitored by serial measurements of potassium, carbon dioxide content, and other parameters as previously described.
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Measurements of Hemodynamics and Peripheral Vascular Resistance
Blood pressure was measured in the right arm positioned at heart level using a large cuff and a standard mercury column sphygmomanometer. Values of three recordings taken at 1-minute intervals with subjects in the sitting position were reported as mean±SEM. Forearm blood flow (FBF) and forearm vascular resistance (FVR) were measured by electrical impedance plethysmography (IPG-104, RJL Systems, Detroit, Mich.) as previously described. 27 - 29 Briefly, to measure FBF, we placed two detecting electrodes 10 cm apart centered on the right forearm and two signal electrodes approximately 20 cm proximal and distal to the area being measured. FBF was then quantitated from the resulting tracings using the backslope projection method of Nyboer. 27 FVR was calculated by dividing the mean arterial pressure (MAP) by FBF. FBF determined by this method exhibits an intraindividual coefficient of variation of less than 3% in our laboratory. 29 ]i was measured from blood samples (=15 mL each) that were collected in EDTA-treated Vacutainer tubes and centrifuged at 200g for 15 minutes at 21°C for the determination of platelet [Ca 2+ ], levels as previously described. 30 Briefly, platelet-rich plasma was incubated in 3 fimol fura-2-acetoxymethyl ester (fura-2) per liter at 37°C for 30 minutes and centrifuged at 650g for 10 minutes at 21°C; the plasma and extracellular fura-2 were removed by aspiration. The platelet pellet was then suspended in a calcium-free HEPES (10 mM) buffer (pH 7.4) and centrifuged at 650g; the platelets were suspended at a concentration of 1 x 10 7 cells/mL in HEPES (10 mM) containing calcium (1.5 mM). We have previously found that this method of preparing platelets by differential centrifugation yields results indistinguishable from those obtained in platelets purified by gel filtration. 30 [Ca 2+ ]i was measured in a model 1680 dual excitation monochromator spectrofluorometer (SPEX Industries, Edison, N.J.) with excitation wavelengths of 340 and 380 nm, an emission wavelength of 505 nm, and entry and exit slits set at 3 nm. The response of [Ca 2+ ], to arginine vasopressin (AVP) was determined by measuring the peak response to 9 /miol AVP per liter, after a stable baseline value for [Ca 2+ ], had been established before AVP was added. The response to AVP is expressed as the percent increase over the baseline [Ca 2+ ],. All measurements were made in a waterjacketed cuvette at 37°C, with continuous stirring. [Ca 2+ ]i was calculated from the ratio of fluorescence at 340 nm to that at 380 nm, as described by Grynkiewicz et al 31 ; the maximal ratio was obtained with 0.7% Triton X-100 and the minimal ratio with 5 mM EGTA-Tris (pH 8.6). 31 
Measurements of Platelet
Statistical Analysis
Statistical time-related changes in hemodynamic and biochemical parameters were evaluated by repeatedmeasures analysis of variance after it was verified that the data were normally distributed. Multiple regression analysis was used to calculate coefficients of correlation among various parameters. When appropriate, the significance of differences was also assessed using Student's t test. All values are expressed as mean±SEM (with number of observations in parentheses); values of p<0.05 were considered significant. Table 1 gives the baseline clinical, hemodynamic, and biochemical data for the 18 obese subjects in this study. The study population included 11 blacks and seven whites, 12 women and six men. The subjects were all more than 30% of ideal body weight (74.3+4.1%). Body mass index for the 18 subjects was 37 Figures 1A and IB illustrate the changes in body weight and MAP during the 12 weeks of the VLCD. Although subjects lost weight each week, significant reductions in group mean weight did not occur until 7-8 weeks because of the variability among subjects ( Figure  1A ). There was a significant reduction in MAP after 3-4 weeks (4.4±1.4 mmHg, p<0.05, w = 18), with a further reduction observed at 7-8 weeks (8.7 ±1.4 mmHg,p<0.01, n = 18). However, there was no significant additional reduction in MAP after 11-12 weeks (n = 10) of the VLCD ( Figure IB) . Diastolic and systolic blood pressures decreased by 11.1±2.1 (p<Q.Q5) and 11.2±2.3 mm Hg (p<0.05, « = 10), respectively, after 12 weeks of the VLCD (Figures 2A and 2B) .
Results
Results of FVR and FBF measurements are illustrated in Figures 3A and 3B . Similar to our observations of MAP, FVR was also reduced in subjects during the 12-week study ( Figure 3A) . After 3-4 weeks of the VLCD, FVR decreased by 7.1 mm Hg/(mL/100 mL per minute), (p<0.01, n = 18). The reduction in FVR was even more pronounced after 7-8 weeks (week 0, 34±2.0; week 7-8, 22+1.2 mm Hg/[mL/100 mL per minute], p<0.001, n = 18). However, although FVR tended to continue to decrease at 11-12 weeks (n=10), it was not significantly different than FVR at 7-8 weeks.
As FVR decreased in subjects during the VLCD ( Figure 3A) , a concomitant increase in FBF was observed ( Figure 3B ). After 7-8 weeks, FBF increased by 54±3% (p<0.001). Although FBF tended to continue to increase at week 11-12 (57±4%), it did not reach a level of significance beyond the FBF observed at week 7-8 (week 0, 2.8±0.2; week 3-4, 3.7±0.2; week 7-8, 4.3±0.2; week 11-12, 4.4±0.2 mL/100 mL per minute; p<0.01).
Changes in FBF were negatively correlated with changes in FVR at 7-8 weeks (r=-0.58, p<0.02), as would be anticipated (data not shown). There was also a significant correlation (r=0.58, p<0.03) between weight loss and the change in FBF observed at weeks 7-8 ( Figure 4A ). However, no significant correlations were observed between changes in either FVR or FBF and any of the other parameters measured during the 12-week VLCD. ]j responses at 7-8 weeks of weight reduction (r=0.512, n = 18,p<0.04) ( Figure 4B ).
FIGURE 3. Line plots show effect of weight loss over time on forearm vascular resistance (panel A) and peripheral blood flow (forearm blood flow) (panel B) in study subjects
Discussion
These data indicate that the weight loss-induced reduction in blood pressure in obese individuals is ]i decreased in obese subjects after 10 weeks of dieting. Our results indicate that reduction in platelet [Ca 2+ ]| occurs within the first month of weight loss and continues to decrease throughout a 12-week VLCD. In the study by Scherrer et al, 11 only those subjects who had a change in body mass index of more than 5% were included in the various parameters analyzed, including the platelet [Ca 2+ ];. Our results indicated that even small reductions in weight (changes in body mass index <5%) are associated with reduced platelet [Ca 2+ ]|. The levels of baseline platelet [Ca 2+ ], observed in our study (38.1±2.8 nM) were lower than those we had observed in our previous study with young nonobese individuals. 29 - 30 Thus, it is possible that these levels change with age, adiposity, or both. These baseline levels were also lower than those observed by Scherrer et al 11 in obese subjects (165 nM). There are several possible explanations for these differences. In our study, we used the dye indicator fura-2, 29 -32 whereas Scherrer et al 11 used the quin-2 method. Differences in autofluorescence, degree of quenching, dye leakage, and reproducibility of results suggest that the fura-2 method is preferable. 21 -2429 - 32 A number of other factors, such as the lag time between collection of blood and dye loading of platelets, increased incubation time in Ca 2+ -supplemented media, and platelet activation and titratable dye leakage from platelets, can all lead to factitiously "high" [Ca 2+ ], determinations. 30 In general, increased caution and awareness of these factors have resulted in increasingly lower values being reported for platelet [Ca 2+ ], levels over the past decade. who showed a correlation between the decreases in platelet [Ca 2+ ]i and diastolic blood pressure at 10 weeks of weight-reduction, we observed no such relation between these parameters at 3-4, 7-8, or 11-12 weeks after the weight-reduction regimen was begun. Similarly, we observed no such relation between reductions in platelet [Ca 2+ ]j and reductions in FVR or increases in FBF. The relatively small decrease in blood pressure associated with weight loss in this study may have accounted for the lack of correlation between platelet [Ca 2+ ], and blood pressure. Perhaps studying more subjects with a greater decrease in blood pressure would uncover such relations. However, this does not explain the positive findings of Scherrer et al, 11 who studied a similar number of subjects (n = 19) at only one time point (10 weeks) after onset of weight reduction. Again, it should be noted that Scherrer et al divided their study population into responders and nonresponders, whereas the present results reflect the entire population studied.
The mechanism involved in the fall in baseline platelet [Ca 2+ ], associated with weight reduction and the accompanying decrease in blood pressure is unclear. It has been suggested 11 that a fall in circulating catecholamines associated with weight loss 5 ]i responses did correlate with decreases in MAP after 2 months of weight reduction in these obese subjects. This observation suggests that changes in AVP-stimulated platelet [Ca 2+ ], may be a more sensitive reflection of the relation between changes in platelet Ca 2+ metabolism and changes in peripheral vascular resistance. More prospective studies including larger numbers of subjects with greater lowering of blood pressure may be necessary to clarify this issue. This is the first study to prospectively evaluate the effects of weight reduction in obese subjects on peripheral vascular resistance and peripheral blood flow. Our data indicate that peripheral vascular resistance was markedly reduced, with accompanying increases in blood flow, within 3-4 weeks of the 12-week weightreduction program. A strong correlation was observed between reductions in body weight and increases in peripheral blood flow, but not vascular resistance on blood pressure. Because vascular resistance is derived from peripheral blood flow and blood pressure measurements, our data suggest that measurement of peripheral blood flow is a more sensitive measure than blood pressure in determining changes in hemodynamics accompanying weight reduction.
Our studies do not rule out the importance of a reduction of cardiac output with weight reduction 44 as another factor involved in the lowering of blood pressure in obese individuals undergoing a weight-loss program. Thus, our data suggest that a reduction in peripheral vascular resistance is an important hemodynamic mechanism involved in blood pressure reduction associated with weight reduction in obese individuals. D B Jacobs, J R Sowers, A Hmeidan, T Niyogi, L Simpson and P R Standley Effects of weight reduction on cellular cation metabolism and vascular resistance.
